• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract: Dolutegravir-containing antiretroviral regimens show effective viral suppression in pregnant women with HIV-1

byConstance Wu
April 22, 2021
in StudyGraphics
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Dolutegravir-based antiretroviral therapy regimens effectively suppressed maternal viral load during pregnancy, supporting their use to prevent vertical transmission.

2. Dolutegravir, emtricitabine, and tenofovir alafenamide fumarate carried relatively low risk of adverse fetal outcomes.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Initiation of antiretroviral therapy (ART) for pregnant women infected with HIV-1 is important for maternal-fetal health; however, there is limited information on ART safety and efficacy in pregnancy. This multicenter, open-label, randomized, controlled, phase 3 clinical trial compares the safety and efficacy of three ART regimens for use in pregnancy. Pregnant women infected with HIV-1 at 14-28 weeks’ gestation and had no previous ART use or pregnancy complications were eligible for this trial. Participants were randomized equally to three ART regimens and stratified by gestational age. The primary outcome was proportion of participants with HIV-1 viral suppression of <200 copies of RNA per mL within 14 days of delivery. Absolute efficacy of each regimen in suppressing viral load and adverse pregnancy outcomes were compared as well. According to study results, regimens containing dolutegravir were most effective at suppressing viral load in pregnant women. Additionally, the dolutegravir, emtricitabine, and tenofovir alafenamide fumarate regimen had the lowest rates of adverse pregnancy outcomes. These results together support the use of dolutegravir along with adjuvant agents emtricitabine and tenofovir alafenamide fumarate to suppress viral load in HIV-1 positive pregnant women.

Click to read the study in The Lancet

Relevant Reading: Neural-Tube Defects with Dolutegravir Treatment from the Time of Conception

In-Depth [randomized controlled trial]: This study included 22 international centers and 643 eligible participants to assess the relative efficacy of three ART regimens: dolutegravir with emtricitabine and tenofovir alafenamide fumarate (TAF); dolutegravir with emtricitabine and tenofovir disoproxil fumarate (TDF); and efavirenz, emtricitabine, and tenofovir disoproxil fumarate. Demographic characteristics were comparable among the three groups. When the results from dolutegravir-containing groups were pooled and compared to the efavirenz-based group, statistically significant differences in the rates of adequate HIV-1 RNA suppression were observed, with estimated 98% suppression in pooled dolutegravir groups compared to 91% suppression in efavirenz group (estimated difference of 6.5% [95% CI 2.0-10.7]; p=0.0052). Adequate viral suppression was defined as HIV-1 RNA <200 copies/mL. This difference persisted even after stratifying participants by viral load at time of enrollment (>200 copies/mL vs. <200 copies/mL). In terms of safety, TAF was associated with lower risk of adverse pregnancy outcomes compared to TDF upon evaluation of a range of adverse events including fetal infection, infant mortality within the first month of life, and congenital abnormalities.

RELATED REPORTS

Long-acting cabotegravir significantly decreases incidence of HIV compared to daily oral tenofovir

Several factors influence health programs conducted in the African American Church

Nasal high-flow therapy improves likelihood of neonatal intubation

This study excluded multiple gestation pregnancies or pregnancies complicated with fetal abnormalities. Additionally, participants with psychiatric complaints or gestational ages outside of the 14-28 week window at time of enrollment were excluded, which amounts to a significant proportion of pregnant women. Despite these limitations, this study contributes to the limited body of data supporting the use of dolutegravir-based ART regimens during pregnancy.

©2020 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: antiretroviralantiretroviral therapyDolutegravirHIVHIV-1neonatalpregnancypregnantpreterm
Previous Post

Lamotrigine offers higher net health benefits and is more cost-effective than levetiracetam and zonisamide as first-line focal epilepsy treatment

Next Post

Comparative outcomes between COVID-19 and influenza patients placed on veno-venous extracorporeal membrane oxygenation

RelatedReports

Gardasil vaccine demonstrates immunogenic response at 10-year follow-up
Chronic Disease

Long-acting cabotegravir significantly decreases incidence of HIV compared to daily oral tenofovir

May 18, 2022
Wellness

Several factors influence health programs conducted in the African American Church

May 18, 2022
Low evidence for glycerin use in preterm infants
Obstetrics

Nasal high-flow therapy improves likelihood of neonatal intubation

May 13, 2022
Prenatal antidepressant exposure may increase risk of poor motor development
Cardiology

Treating mild chronic hypertension associated with better pregnancy outcome

May 13, 2022
Next Post
Parental hopes for critically ill children are dynamic

Comparative outcomes between COVID-19 and influenza patients placed on veno-venous extracorporeal membrane oxygenation

#VisualAbstract: Liver metastases and LDH levels may be superior prognostic biomarkers for patients with metastatic melanoma

#VisualAbstract: No differences in survival in patients with esophageal cancer treated with neoadjuvant chemotherapy or chemoradiotherapy followed by esophagectomy

Combined MRI and NIH stroke scores may predict stroke prognosis

Levetiracetam not clinically effective nor cost-effective compared to valproate for newly diagnosed generalized or unclassified epilepsy

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Long-acting cabotegravir significantly decreases incidence of HIV compared to daily oral tenofovir
  • Oral methylprednisolone may reduce risk of progressive renal failure in patients with IgA nephropathy: TESTING Trial
  • #VisualAbstract: Adjuvant capecitabine improves long-term survival in early breast cancer
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.